Terms: = Ovarian cancer AND NRG1, ENSG00000157168, 3084, SMDF, NDF, HRGA, HRG1, HGL, GGF2, GGF, ARIA AND Treatment
12 results:
1. Bone morphogenetic protein-9 downregulates StAR expression by inducing snail expression via SMAD1/5/8 signaling in human granulosa-lutein cells.
Liu B; Fu B; Zhou S; Wang H; Bi B; Guo M; Cheng JC; Fang L
Mol Cell Endocrinol; 2024 Mar; 582():112126. PubMed ID: 38109991
[TBL] [Abstract] [Full Text] [Related]
2. Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma.
Murumägi A; Ungureanu D; Khan S; Arjama M; Välimäki K; Ianevski A; Ianevski P; Bergström R; Dini A; Kanerva A; Koivisto-Korander R; Tapper J; Lassus H; Loukovaara M; Mägi A; Hirasawa A; Aoki D; Pietiäinen V; Pellinen T; Bützow R; Aittokallio T; Kallioniemi O
Br J Cancer; 2023 Feb; 128(4):678-690. PubMed ID: 36476658
[TBL] [Abstract] [Full Text] [Related]
3. The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic
Odintsov I; Lui AJW; Sisso WJ; Gladstone E; Liu Z; Delasos L; Kurth RI; Sisso EM; Vojnic M; Khodos I; Mattar MS; de Stanchina E; Leland SM; Ladanyi M; Somwar R
Clin Cancer Res; 2021 Jun; 27(11):3154-3166. PubMed ID: 33824166
[TBL] [Abstract] [Full Text] [Related]
4. Clinical perspectives of BET inhibition in ovarian cancer.
Andrikopoulou A; Liontos M; Koutsoukos K; Dimopoulos MA; Zagouri F
Cell Oncol (Dordr); 2021 Apr; 44(2):237-249. PubMed ID: 33469840
[TBL] [Abstract] [Full Text] [Related]
5. nrg1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors.
Miyake TM; Pradeep S; Bayraktar E; Stur E; Handley KF; Wu SY; Rodriguez-Aguayo C; Lee JS; Lopez-Berestein G; Coleman RL; Sood AK
Mol Cancer Ther; 2020 Aug; 19(8):1727-1735. PubMed ID: 32499298
[TBL] [Abstract] [Full Text] [Related]
6. Identification of the key genes associated with chemotherapy sensitivity in ovarian cancer patients.
Zheng H; Zhang M; Ma S; Yang W; Xie S; Wang Y; Liu Y; Kai J; Ma Q; Lu R; Guo L
Cancer Med; 2020 Jul; 9(14):5200-5209. PubMed ID: 32441484
[TBL] [Abstract] [Full Text] [Related]
7. TGF-β1 induces VEGF expression in human granulosa-lutein cells: a potential mechanism for the pathogenesis of ovarian hyperstimulation syndrome.
Fang L; Li Y; Wang S; Li Y; Chang HM; Yi Y; Yan Y; Thakur A; Leung PCK; Cheng JC; Sun YP
Exp Mol Med; 2020 Mar; 52(3):450-460. PubMed ID: 32152452
[TBL] [Abstract] [Full Text] [Related]
8. Response to ERBB3-Directed Targeted Therapy in
Drilon A; Somwar R; Mangatt BP; Edgren H; Desmeules P; Ruusulehto A; Smith RS; Delasos L; Vojnic M; Plodkowski AJ; Sabari J; Ng K; Montecalvo J; Chang J; Tai H; Lockwood WW; Martinez V; Riely GJ; Rudin CM; Kris MG; Arcila ME; Matheny C; Benayed R; Rekhtman N; Ladanyi M; Ganji G
Cancer Discov; 2018 Jun; 8(6):686-695. PubMed ID: 29610121
[No Abstract] [Full Text] [Related]
9. BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin.
Paul BT; Blanchard Z; Ridgway M; ElShamy WM
Oncogene; 2015 Jun; 34(23):3036-52. PubMed ID: 25132263
[TBL] [Abstract] [Full Text] [Related]
10. An activated ErbB3/nrg1 autocrine loop supports in vivo proliferation in ovarian cancer cells.
Sheng Q; Liu X; Fleming E; Yuan K; Piao H; Chen J; Moustafa Z; Thomas RK; Greulich H; Schinzel A; Zaghlul S; Batt D; Ettenberg S; Meyerson M; Schoeberl B; Kung AL; Hahn WC; Drapkin R; Livingston DM; Liu JF
Cancer Cell; 2010 Mar; 17(3):298-310. PubMed ID: 20227043
[TBL] [Abstract] [Full Text] [Related]
11. Essential roles of Her2/erbB2 in cardiac development and function.
Negro A; Brar BK; Lee KF
Recent Prog Horm Res; 2004; 59():1-12. PubMed ID: 14749494
[TBL] [Abstract] [Full Text] [Related]
12. Heregulin induces increase in sensitivity of an erbB-2-overexpressing breast cancer cell type to lysis by lymphokine-activated killer cells.
Cardillo M; Yankelevich B; Mazumder A; Lupu R
Cancer Immunol Immunother; 1996 Sep; 43(1):19-25. PubMed ID: 8917631
[TBL] [Abstract] [Full Text] [Related]
